Upcoming Pfizer launches
Executive Summary
Anti-migraine agent Relpax (eletriptan) "is probably one of those things that is going to be a year-end approval kind of situation," Pfizer Global R&D President John Niblack told a July 26 conference call. Pfizer has responded to a 1999 "approvable" letter, and FDA has six months to review the resubmission, he said. The antihistamine/ decongestant combo Zyrtec D should be approved during the first quarter, Pfizer said